Investment year: 2018

Funding raised following LSF investment: 35 MCHF Series A


Recombinant IL-2 (Proleukin®) is a first generation immunotherapy agent with some efficacy in metastatic melanoma and kidney carcinoma but also dose limiting toxicity. Anaveon is developing next generation IL-2 pharmacological agents to markedly increase the efficacy/safety therapeutic window of Proleukin®. Our approach is based on a highly selective antibody which re-directs IL-2 away from regulatory T cells to CD8 effector T cells. We have demonstrated robust efficacy in preclinical tumor models and a broad efficacy/safety window.